CCO Treatment Updates
Evolutions in VEGF-Targeted Therapy for GBM: Recent Advances and Ongoing Research
Module
The Changing Landscape of Glioblastoma Multiforme
|
|
|
James J. Vredenburgh, MD, reviews the biology of glioblastomas and discusses currently available and investigational anti-VEGF therapies for this disease.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Evaluate the prevalence of glioblastoma and predominant locations of occurrence
- Assess the differences between primary and secondary glioblastoma
- Analyze the evidence regarding resection, radiation, and chemotherapy for the treatment of glioblastoma
- Evaluate the factors that influence treatment decisions and the various treatment regimens and combinations available for newly diagnosed and recurrent glioblastoma
Abstract
|
Interactive Virtual Presentations
Expanding Treatment Options for Glioblastoma: Past, Present, and Future
|
|
|
In this case-based Interactive Virtual Presentation, Timothy Cloughesy, MD, discusses current data in current treatment modalities for patients with glioblastoma.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Assess the role of surgery and radiotherapy in treating patients with glioblastoma
- Analyze the development of pseudo-response and pseudo-progression in glioblastoma
- Evaluate treatment options for glioblastoma patients who have failed bevacizumab therapy
|
Slideset: Expanding Treatment Options for Glioblastoma: Past, Present, and Future
 |
|
Download slides on the most recurrent data in glioblastoma therapies.
Format: Microsoft PowerPoint (.ppt) |
File size: 5.78 MB
| Date posted: 12/16/2009
|
Optimizing Patient Outcomes With Angiogenic Inhibitors for the Treatment of GBM
|
|
|
Laurie Rice, RN, MSN, NP, highlights optimal strategies for preventing and coping with potential adverse events during antiangiogenesis therapy for glioblastoma.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe adverse events commonly associated with anti-VEGF therapy
- Apply recommended adverse event monitoring and mitigating strategies when treating patients with anti-VEGF therapy for glioblastoma
- Use recommended procedures for managing patients with glioblastoma who are experiencing adverse events such as hypertension, proteinuria, or bleeding during anti-VEGF therapy
|
Slideset: Optimizing Patient Outcomes With Angiogenic Inhibitors for the Treatment of GBM
 |
|
Laurie Rice, RN, MSN, NP, provides an overview of monitoring and management strategies for adverse events associated with antiangiogenesis therapy in patients with glioblastoma.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.18 MB
| Date posted: 1/13/2010
|
Disclaimer:
The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|